Trizivir

Trizivir is a brand name of abacavir/lamivudine/zidovudine, approved by the FDA in the following formulation(s):

TRIZIVIR (abacavir sulfate; lamivudine; zidovudine - tablet; oral)

• 
  Manufacturer: VIIV HLTHCARE
  
  Approval date: November 14, 2000
  
  Strength(s): EQ 300MG BASE;150MG;300MG ^[RLD]

Has a generic version of Trizivir been approved?

No. There is currently no therapeutically equivalent version of Trizivir available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trizivir. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Therapeutic nucleosides
  Patent 5,034,394
  Issued: July 23, 1991
  Inventor(s): Daluge; Susan M.
  Assignee(s): Burroughs Wellcome Co.
  The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.
  
  Patent expiration dates:
  
  
  • December 18, 2011
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • June 18, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Crystalline oxathiolane derivatives
  Patent 5,905,082
  Issued: May 18, 1999
  Inventor(s): Roberts; Tony Gordon & Evans; Paul
  Assignee(s): Glaxo Group Limited
  (-)cis-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(IH)-pyrimidine-2-on e in crystalline form, in particular as needle-shaped or bypyramidyl crystals, pharmaceutical formulations thereof, methods for their preparation and their use in medicine.
  
  Patent expiration dates:
  
  
  • May 18, 2016
    
    ✓ 
    Patent use: TREATMENT OF HIV
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • November 18, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Carbocyclic nucleoside hemisulfate and its use in treating viral infections
  Patent 6,294,540
  Issued: September 25, 2001
  Inventor(s): Brodie; Alastair Couper & Jones; Martin Francis & Seager; John Frederick & Wallis; Christopher John
  Assignee(s): Glaxo Wellcome Inc.
  The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol or a solvate of it is used in the treatment of viral infections.
  
  Patent expiration dates:
  
  
  • May 14, 2018
    
    ✓ 
    Patent use: METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • November 14, 2018
    
    ✓ 
    Patent use: METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
    ✓ 
    Pediatric exclusivity
  
  



• 
  Synergistic combinations of zidovudine, 1592U89 and 3TC
  Patent 6,417,191
  Issued: July 9, 2002
  Inventor(s): David Walter; Barry & Martha Heider; St. Clair
  Assignee(s): GlaxoSmithKline
  The present invention relates to therapeutic combinations of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol (1592U89), 3′-azido-3′-deoxythymidine (zidovudine) and (2R,cis)-4-amino-]-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (3TC) (or, alternatively to 3TC, (2R,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (FTC)) which have anti-HIV activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.
  
  Patent expiration dates:
  
  
  • March 28, 2016
    
    ✓ 
    Patent use: TREATMENT OF HIV
    ✓ 
    Drug product
  
  

See also...

• Trizivir Consumer Information (Drugs.com)
• Trizivir Consumer Information (Wolters Kluwer)
• Trizivir Consumer Information (Cerner Multum)
• Trizivir Advanced Consumer Information (Micromedex)
• Abacavir/Lamivudine/Zidovudine Consumer Information (Wolters Kluwer)
• Abacavir, lamivudine, and zidovudine Consumer Information (Cerner Multum)
• Abacavir-lamivudine-zidovudine Consumer Information (Cerner Multum)
• Abacavir, lamivudine, and zidovudine Advanced Consumer Information (Micromedex)